These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 27481900

  • 1. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.
    Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, Vonkeman HE, Adang E, van de Laar MA, van Riel PL.
    J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900
    [Abstract] [Full Text] [Related]

  • 2. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
    Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Kalstad S, Kaufmann C, Rødevand E, Kvien TK.
    Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
    [Abstract] [Full Text] [Related]

  • 3. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
    Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, González MÁ, Monjo I, Nuño L, Nozal P, Pascual-Salcedo D, Balsa A.
    Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
    [Abstract] [Full Text] [Related]

  • 4. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM.
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [Abstract] [Full Text] [Related]

  • 5. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, Elbez Y, Rauch C.
    Arthritis Res Ther; 2018 Jan 02; 20(1):1. PubMed ID: 29329602
    [Abstract] [Full Text] [Related]

  • 6. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E.
    Rheumatology (Oxford); 2014 Nov 02; 53(11):1984-93. PubMed ID: 24907147
    [Abstract] [Full Text] [Related]

  • 7. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD, Baker JF, Ogdie A.
    J Rheumatol; 2020 Jun 01; 47(6):826-834. PubMed ID: 31474599
    [Abstract] [Full Text] [Related]

  • 8. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
    Mease PJ, Accortt NA, Rebello S, Etzel CJ, Harrison RW, Aras GA, Gharaibeh MMF, Greenberg JD, Collier DH.
    Rheumatol Int; 2019 Sep 01; 39(9):1547-1558. PubMed ID: 31321485
    [Abstract] [Full Text] [Related]

  • 9. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
    Zhao J, Zhou W, Wu Y, Ji P, Yang L, Yan X, Zhang Z.
    BMC Med Inform Decis Mak; 2021 Mar 04; 21(1):83. PubMed ID: 33663487
    [Abstract] [Full Text] [Related]

  • 10. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR, Harrison DJ, Cannon GW.
    Arthritis Care Res (Hoboken); 2017 Mar 04; 69(3):313-322. PubMed ID: 27273801
    [Abstract] [Full Text] [Related]

  • 11. Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hernández-Cruz B, Márquez-Saavedra E, Caliz-Caliz R, Navarro-Sarabia F.
    Arthritis Res Ther; 2016 Nov 08; 18(1):259. PubMed ID: 27821150
    [Abstract] [Full Text] [Related]

  • 12. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Ma M, Walker D, Heslin M, Patel A, Kingsley G.
    Health Technol Assess; 2014 Oct 08; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [Abstract] [Full Text] [Related]

  • 13. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.
    Ann Rheum Dis; 2018 Sep 08; 77(9):1276-1282. PubMed ID: 29730637
    [Abstract] [Full Text] [Related]

  • 14. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
    Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group.
    Ann Rheum Dis; 2015 Jun 08; 74(6):970-8. PubMed ID: 25710471
    [Abstract] [Full Text] [Related]

  • 15. Determinants associated with work participation in patients with established rheumatoid arthritis taking tumor necrosis factor inhibitors.
    Manders SH, Kievit W, Braakman-Jansen AL, Brus HL, Hendriks L, Fransen J, van de Laar MA, van Riel PL.
    J Rheumatol; 2014 Jul 08; 41(7):1263-9. PubMed ID: 24833758
    [Abstract] [Full Text] [Related]

  • 16. Treatment Response to Tumor Necrosis Factor Inhibitors and Methotrexate Monotherapy in Adults With Juvenile Idiopathic Arthritis: Data From NOR-DMARD.
    Bardan I, Fagerli KM, Sexton J, Kvien TK, Bakland G, Mielnik P, Hu Y, Lien G, Flatø B, Molberg Ø, Kristianslund EK, Aga AB.
    J Rheumatol; 2023 Apr 08; 50(4):538-547. PubMed ID: 36379571
    [Abstract] [Full Text] [Related]

  • 17. Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.
    Thomas ML, Shaddick G, Charlton R, Cavill C, Holland R, Iannone F, Lapadula G, Lopriore S, Závada J, Uher M, Pavelka K, Szczuková L, Sidiropoulos P, Flouri I, Drosos A, Möller B, Nissen MJ, Müller RB, Scherer A, McHugh N, Nightingale A.
    J Rheumatol; 2021 Jan 01; 48(1):48-57. PubMed ID: 32238520
    [Abstract] [Full Text] [Related]

  • 18. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH.
    Health Technol Assess; 2018 Jun 01; 22(34):1-280. PubMed ID: 29900829
    [Abstract] [Full Text] [Related]

  • 19. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, Greenberg JD, Curtis JR.
    Arthritis Care Res (Hoboken); 2015 Dec 01; 67(12):1671-8. PubMed ID: 26018115
    [Abstract] [Full Text] [Related]

  • 20. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R.
    J Rheumatol; 2018 Feb 01; 45(2):177-187. PubMed ID: 29142036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.